Mural Oncology's acquisition by XRA 5 Corp. is sanctioned by the High Court of Ireland, effective December 5, 2025.
Quiver AI Summary
Mural Oncology plc announced that the High Court of Ireland has approved a scheme of arrangement allowing XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, to acquire Mural's entire share capital. This acquisition is expected to take effect once the Court Order is delivered to the Irish Registrar of Companies on December 5, 2025, with Mural shares ceasing to trade on Nasdaq the day before. Shareholders will receive cash compensation under the terms of the scheme, anticipated to be distributed shortly after the effective date, but no later than December 19, 2025. The announcement includes forward-looking statements regarding the transaction and advises adherence to Irish Takeover Rules concerning disclosures by interested parties. The release is intended only for jurisdictions where distribution complies with relevant laws.
Potential Positives
- The High Court of Ireland has sanctioned the scheme of arrangement, allowing Mural's acquisition to move forward, which is a crucial step in the acquisition process.
- Mural shareholders will receive cash consideration in exchange for their shares as part of the acquisition, providing immediate financial benefits to investors.
- The acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, indicates confidence and investment in Mural's future by a larger entity within the sector.
- The acquisition is expected to streamline operations and possibly enhance the company's market position, potentially leading to future growth opportunities following the effective date.
Potential Negatives
- Cancellation of Mural Shares from trading on Nasdaq indicates a significant transition from public to private ownership, which may signal reduced market confidence.
- The press release highlights potential risks and uncertainties regarding the Acquisition's closing conditions, which could destabilize shareholder sentiment.
- Shareholders face a deadline with no trading post-4 December 2025, potentially limiting financial options and liquidity for investors before the acquisition is finalized.
FAQ
What recent corporate action did Mural Oncology announce?
Mural Oncology announced that the High Court of Ireland has sanctioned a scheme of arrangement for its acquisition by XRA 5 Corp.
When will the acquisition of Mural by XRA 5 Corp. become effective?
The acquisition is expected to become effective on 5 December 2025 upon delivery of the Court Order to the Irish Registrar of Companies.
What is the significance of the Scheme for Mural shareholders?
The Scheme will facilitate the acquisition of Mural's entire issued share capital by XRA 5 Corp., affecting shareholder ownership.
When will Mural's shares cease trading on Nasdaq?
Trading of Mural Shares on Nasdaq is expected to end on 4 December 2025, the day before the acquisition becomes effective.
How will shareholders receive payment under the terms of the Scheme?
Shareholders will receive cash consideration via distribution of cheques or crediting of DTC participant accounts following the Effective Date.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MURA Insider Trading Activity
$MURA insiders have traded $MURA stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
- CAROLINE LOEW (Chief Executive Officer) sold 12,531 shares for an estimated $30,475
- ADAM D. CUTLER (Chief Financial Officer) sold 7,148 shares for an estimated $14,939
- MAIKEN KESON-BROOKES (See Remarks) has made 0 purchases and 2 sales selling 4,730 shares for an estimated $11,730.
- VICKI L GOODMAN (Chief Medical Officer) sold 5,036 shares for an estimated $10,474
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MURA Hedge Fund Activity
We have seen 26 institutional investors add shares of $MURA stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 1,722,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,253,340
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,323,877 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,740,425
- PROSIGHT MANAGEMENT, LP removed 900,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,862,999
- SOLAS CAPITAL MANAGEMENT, LLC removed 887,995 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,193,347
- ACORN CAPITAL ADVISORS, LLC removed 653,779 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,353,322
- OMERS ADMINISTRATION CORP added 511,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,057,770
- LMR PARTNERS LLP removed 500,000 shares (-96.8%) from their portfolio in Q3 2025, for an estimated $1,034,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “ Scheme ”) pursuant to which XRA 5 Corp. (“ Sub ”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA Royalty ”), will acquire the entire issued and to be issued share capital of Mural (the “ Acquisition ”).
The Scheme and the Acquisition will become effective on delivery of the Court Order to the Irish Registrar of Companies.
Delivery of the Court Order to the Irish Registrar of Companies is expected to occur, and the Acquisition is expected to become effective, on 5 December 2025 (the “ Effective Date ”). Accordingly, 4 December 2025 is expected to be the last date on which trading of Mural Shares on the Nasdaq will occur. Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market is expected to occur with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.
Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, subject to the delivery of the Court Order to the Irish Registrar of Companies on 5 December 2025, all consideration payable by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.
Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
Enquiries
Mural Oncology plc
[email protected]
Lucid Capital Markets, LLC (Financial Adviser to Mural)
570 Lexington Ave, 40th Floor
New York, NY 10022
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding Mural, XOMA Royalty and Sub’s intention to consummate the Acquisition and the expected timing of the closing of the Acquisition.
These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: uncertainties as to the possibility that closing conditions for the Acquisition may not be satisfied or waived; the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders; the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market; the other risks and uncertainties pertaining to Mural’s business, including those described in Mural’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural’s subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.
Statements Required by the Irish Takeover Rules
The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority (“ FINRA ”) in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this announcement, any statement or other matter or arrangement referred to herein or otherwise.
Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this announcement.
Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.
Disclosure Requirements of the Irish Takeover Rules
Under Rule 8.3(b) of the Irish Takeover Rules, any person who is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of Mural must disclose all “dealings” in such “relevant securities” during the “offer period”. The disclosure of a “dealing” in “relevant securities” by a person to whom Rule 8.3(b) applies must be made by no later than 3:30pm (U.S. Eastern Time) on the “business day” following the date of the relevant “dealing”. A dealing disclosure must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person’s interests and short positions in any “relevant securities” of Mural.
All “dealings” in “relevant securities” of Mural by a bidder, or by any party acting in concert with a bidder, must also be disclosed by no later than 12:00 noon (U.S. Eastern Time) on the “business day” following the date of the relevant “dealing”.
If two or more persons co-operate on the basis of an agreement, either express or tacit, either oral or written, to acquire an “interest” in “relevant securities” of Mural, they will be deemed to be a single person for the purpose of Rule 8.3(a) and (b) of the Irish Takeover Rules.
A disclosure table, giving details of the companies in whose “relevant securities” dealing disclosures should be made, can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie .
“Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel’s website.
If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, please consult the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.
General
The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.
Publication on a Website
In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.